Clinical Report: BLAST Shows Superior Prognostic Accuracy for Survival Compared to CPSS in Chinese Patients with Chronic Myelomonocytic Leukemia
Overview
This study evaluates the prognostic performance of the BLAST and CPSS models in Chinese patients with chronic myelomonocytic leukemia (CMML). Findings indicate that BLAST demonstrates prognostic accuracy for overall survival compared to CPSS.
Background
Chronic myelomonocytic leukemia (CMML) is a heterogeneous myeloid malignancy with variable patient prognoses. Accurate risk stratification is essential for identifying high-risk patients. Existing prognostic models, including CPSS and CPSS-mol, have limitations.
Data Highlights
Variable
Hazard Ratio (HR)
95% Confidence Interval (CI)
P-value
Moderate Anemia
2.55
1.66–5.60
0.02
Severe Anemia
3.17
1.56–6.41
0.001
PB Blast ≥2%
1.79
1.10–2.92
0.019
Adverse Karyotype
1.85
1.09–3.14
0.023
ASXL1 Mutation
1.66
1.01–2.72
0.044
TP53 Mutation
3.21
1.65–6.25
0.001
Key Findings
BLAST and BLAST-mol models outperform CPSS and CPSS-mol in prognostic accuracy.
Severe anemia and TP53 mutation are independent poor prognostic factors for overall survival.
Median overall survival varies significantly across CPSS risk groups.
54.4% of patients had died by the last follow-up, indicating a high mortality rate in this cohort.
Most frequently mutated genes included ASXL1, TET2, and SRSF2.
Clinical Implications
The findings indicate that the BLAST model may provide a prognostic tool for clinicians managing CMML in Chinese patients. Identifying patients with severe anemia and TP53 mutations is important.
Conclusion
The study presents the prognostic accuracy of the BLAST model compared to traditional scoring systems in predicting survival outcomes for Chinese patients with CMML.
Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
